Teladoc Health (NYSE:TDOC) Given New $6.00 Price Target at Stifel Nicolaus

Teladoc Health (NYSE:TDOC) had its target price lowered by Stifel Nicolaus from $8.00 to $6.00 in a research report report published on Thursday morning,Benzinga reports. Stifel Nicolaus currently has a hold rating on the health services provider’s stock.

Several other brokerages also recently commented on TDOC. Evercore cut their target price on Teladoc Health from $9.00 to $8.00 and set an “in-line” rating for the company in a research note on Thursday, October 30th. Citigroup cut their price objective on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Friday, January 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Teladoc Health in a research note on Monday, December 29th. Barclays began coverage on shares of Teladoc Health in a report on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 price target for the company. Finally, Bank of America decreased their price target on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Tuesday, November 25th. Four investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.80.

Teladoc Health Stock Performance

NYSE TDOC opened at $5.35 on Thursday. The firm has a market cap of $949.46 million, a P/E ratio of -4.69 and a beta of 2.12. The company has a quick ratio of 2.60, a current ratio of 2.70 and a debt-to-equity ratio of 0.71. The company’s 50 day moving average is $6.03 and its 200-day moving average is $7.21. Teladoc Health has a 12-month low of $4.40 and a 12-month high of $10.02.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. The business had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.09%. Teladoc Health’s revenue was up .3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Sell-side analysts predict that Teladoc Health will post -1.16 earnings per share for the current year.

Insider Activity at Teladoc Health

In other news, insider Fernando M. Rodrigues sold 4,209 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $7.48, for a total value of $31,483.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Charles Divita III sold 17,138 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $7.63, for a total value of $130,762.94. Following the transaction, the chief executive officer owned 201,036 shares in the company, valued at $1,533,904.68. This trade represents a 7.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 33,288 shares of company stock valued at $251,684. 0.58% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TDOC. Vanguard Group Inc. lifted its holdings in shares of Teladoc Health by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock worth $169,372,000 after acquiring an additional 891,732 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Teladoc Health by 8.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 7,494,255 shares of the health services provider’s stock worth $52,459,000 after purchasing an additional 605,061 shares during the last quarter. Geode Capital Management LLC boosted its position in Teladoc Health by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 4,188,313 shares of the health services provider’s stock valued at $29,324,000 after buying an additional 18,394 shares during the period. Jupiter Asset Management Ltd. grew its stake in shares of Teladoc Health by 293.9% during the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock valued at $27,021,000 after buying an additional 2,880,008 shares during the last quarter. Finally, Nuveen LLC grew its stake in shares of Teladoc Health by 38.7% during the fourth quarter. Nuveen LLC now owns 2,659,662 shares of the health services provider’s stock valued at $18,618,000 after buying an additional 742,240 shares during the last quarter. 76.82% of the stock is currently owned by institutional investors.

Key Headlines Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 beat and narrower loss: Teladoc reported revenue of $642.3M (above estimates) and GAAP loss per share of $0.14 (better than consensus), driven by international growth and strength in Integrated Care; investors view the improved bottom line as a near-term positive. Teladoc Tops Q4 Earnings Estimates on International Growth & Lower Costs
• Positive Sentiment: Selective analyst support: Some firms are staying constructive (Bank of America upgraded to Buy, Piper Sandler reaffirmed Overweight, Canaccord remains a Buy despite lowering its PT), which bolsters demand from buyers who focus on recovery potential. Demystifying Teladoc Health: Insights From 8 Analyst Reviews
• Neutral Sentiment: Midterm growth roadmap: Management projects FY2026 revenue of roughly $2.47B–$2.59B and emphasized investments in AI, insurance relationships and international expansion — initiatives that support longer-term upside but will take time to materialize. Teladoc projects $2.47B–$2.59B revenue in 2026
• Negative Sentiment: Cautious forward guidance: Q1 2026 revenue guidance ($598M–$620M) and EPS guidance (-$0.45 to -$0.35) came in below Wall Street expectations, and FY EPS guidance (-$1.10 to -$0.70) is wider/weaker than consensus — a key reason for mixed investor reactions despite the quarter’s beat. Teladoc Health Reports Fourth Quarter and Full Year 2025 Results
• Negative Sentiment: Analyst price-target cuts: Several firms trimmed price targets (BMO, TD Cowen, Stifel, Wells Fargo, Leerink) and moved to Market Perform/Hold ratings in response to the softer outlook, adding selling pressure for investors focused on nearer-term valuation and earnings visibility. Analyst price-target updates

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.